title: Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma.
abstract: Rose Bengal is a novel injectable agent that has been evaluated as a rational treatment strategy for melanoma patients with recurrent unresectable local/regional metastases accessible for intralesional injection. PV-10 (10% Rose Bengal) has completed phase 1 and phase 2 multi-center clinical trials demonstrating significant local/regional disease control and also responses in non-injected regional bystander lesions and distant metastases. The published results of studies that have assessed PV-10 are presented, and the rationale for combining its use with recently approved immunotherapeutic agents is discussed.
authors: Department of Surgical Oncology, Melanoma Section, M. D. Anderson Cancer Center, Houston, Texas.
authors: Merrick I
authors: MI
authors: Ross
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D015552:Injections, Intralesional; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D012395:Rose Bengal / Q000008:administration & dosage*
chemical_list: D012395:Rose Bengal
keywords: intralesional therapy; melanoma; treatment